$JSPR
Jasper Therapeutics, Inc. Stock $jspr

$jspr Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023084970 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.890M	$4.510M	$3.686M
YoY Change	-12.88%	22.35%	27.5%
% of Gross Profit
Research & Development	$13.84M	$14.85M	$9.022M
YoY Change	49.05%	64.58%	25.51%
% of Gross Profit
Depreciation & Amortization	$283.0K	$300.0K	$268.0K
YoY Change	3.66%	11.94%	103.03%
% of Gross Profit
Operating Expenses	$17.73M	$19.36M	$12.71M
YoY Change	28.94%	52.36%	26.08%
Operating Profit		-$19.36M	-$12.71M
YoY Change		52.36%	26.08%
Interest Expense	$1.234M	$1.430M	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$90.00K	$390.0K	$845.0K
YoY Change	-116.79%	-53.85%	-87.34%
Pretax Income	-$16.58M	-$17.54M	-$11.86M
YoY Change	25.51%	47.85%	247.68%
Income Tax
% Of Pretax Income
Net Earnings	-$16.58M	-$17.54M	-$11.86M
YoY Change	25.51%	47.89%	247.68%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.16	-$0.32
Diluted Earnings Per Share	-$1.50	-$0.16	-$0.32
COMMON SHARES
Basic Shares Outstanding	111.6M shares	110.8M shares	36.57M shares
Diluted Shares Outstanding		109.7M shares	36.57M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$86.89M	$103.9M	$50.95M
YoY Change	127.16%	103.93%	-49.51%
Cash & Equivalents	$86.89M	$103.9M	$50.95M
Short-Term Investments
Other Short-Term Assets	$65.00K	$1.100M	$430.0K
YoY Change	-73.58%	155.81%	-64.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables		$18.00K	$117.0K
Total Short-Term Assets	$88.94M	$105.2M	$52.41M
YoY Change	113.12%	100.76%	-48.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.727M	$2.780M	$3.759M
YoY Change	-23.57%	-26.04%	-15.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.343M	$411.0K	$543.0K
YoY Change	76.94%	-24.31%
Total Long-Term Assets	$5.954M	$5.187M	$6.699M
YoY Change	-10.2%	-22.57%	39.39%
TOTAL ASSETS
Total Short-Term Assets	$88.94M	$105.2M	$52.41M
Total Long-Term Assets	$5.954M	$5.187M	$6.699M
Total Assets	$94.89M	$110.4M	$59.11M
YoY Change	96.22%	86.78%	-44.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.149M	$3.256M	$3.117M
YoY Change	134.67%	4.46%	38.72%
Accrued Expenses	$7.908M	$8.200M	$3.488M
YoY Change	54.97%	135.09%	-45.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.37M	$11.91M	$7.421M
YoY Change	75.15%	60.44%	-18.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.264M	$2.297M	$707.0K
YoY Change	-3.78%	224.89%	-96.37%
Total Long-Term Liabilities	$2.264M	$2.297M	$707.0K
YoY Change	-3.78%	224.89%	-96.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.37M	$11.91M	$7.421M
Total Long-Term Liabilities	$2.264M	$2.297M	$707.0K
Total Liabilities	$16.45M	$16.27M	$11.55M
YoY Change	32.98%	40.94%	-59.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$169.6M	-$153.0M	-$91.92M
YoY Change	61.32%	66.44%
Common Stock	$1.000K	$11.00K	$4.000K
YoY Change	-75.0%	175.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$78.44M	$94.13M	$47.57M
YoY Change
Total Liabilities & Shareholders Equity	$94.89M	$110.4M	$59.11M
YoY Change	96.22%	86.78%	-44.87%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$16.58M	-$17.54M	-$11.86M
YoY Change	25.51%	47.89%	247.68%
Depreciation, Depletion And Amortization	$283.0K	$300.0K	$268.0K
YoY Change	3.66%	11.94%	103.03%
Cash From Operating Activities	-$16.48M	-$11.98M	-$9.643M
YoY Change	30.31%	24.24%	35.66%
INVESTING ACTIVITIES
Capital Expenditures	$230.0K	$0.00	-$222.0K
YoY Change	180.49%	-100.0%	-52.77%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$230.0K	$0.00	-$222.0K
YoY Change	180.49%	-100.0%	-52.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-271.0K	30.00K	1.000K
YoY Change	-1067.86%	2900.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-16.48M	-11.98M	-9.643M
Cash From Investing Activities	-230.0K	0.000	-222.0K
Cash From Financing Activities	-271.0K	30.00K	1.000K
Net Change In Cash	-16.98M	-11.95M	-9.864M
YoY Change	33.7%	21.15%	-111.72%
FREE CASH FLOW
Cash From Operating Activities	-$16.48M	-$11.98M	-$9.643M
Capital Expenditures	$230.0K	$0.00	-$222.0K
Free Cash Flow	-$16.71M	-$11.98M	-$9.421M
YoY Change	31.28%	27.16%	41.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	jspr	Common Stock Warrant Liability CommonStockWarrantLiability		usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109720741	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39138
	dei	Entity Registrant Name EntityRegistrantName	JASPER THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2984849
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2200 Bridge Pkwy
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite #102
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
	dei	City Area Code CityAreaCode	(650)
	dei	Local Phone Number LocalPhoneNumber	549-1400
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	111575261	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103867000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38250000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	663000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1351000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2818000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	105218000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	41731000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2780000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3568000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1579000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1886000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	417000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	417000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	411000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	759000	usd
CY2023Q3	us-gaap	Assets Assets	110405000	usd
CY2022Q4	us-gaap	Assets Assets	48361000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3256000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1768000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	945000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	865000	usd
CY2023Q3	jspr	Current Portion Of Earnout Liability CurrentPortionOfEarnoutLiability	28000	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7677000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4432000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11906000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7065000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2069000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2786000	usd
CY2022Q4	jspr	Common Stock Warrant Liability CommonStockWarrantLiability	150000	usd
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	18000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2297000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2353000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	16272000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12372000	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	492000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	492000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110850413	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110850413	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38045677	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38045677	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	247141000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	141120000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-153019000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105135000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	94133000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35989000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	110405000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48361000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14848000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9022000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37950000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25345000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4514000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3686000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13186000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12104000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	19362000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	12708000	usd
	us-gaap	Operating Expenses OperatingExpenses	51136000	usd
	us-gaap	Operating Expenses OperatingExpenses	37449000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19362000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12708000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-51136000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-37449000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1433000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	259000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3965000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	353000	usd
CY2023Q3	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-334000	usd
CY2022Q3	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-422000	usd
	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	10000	usd
	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-5640000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-155000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	575000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7050000	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	51000	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	9000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-128000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-68000	usd
CY2023Q3	us-gaap	Other Income OtherIncome	1818000	usd
CY2022Q3	us-gaap	Other Income OtherIncome	845000	usd
	us-gaap	Other Income OtherIncome	3252000	usd
	us-gaap	Other Income OtherIncome	12975000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-17544000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11863000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47884000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24474000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109720741	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36565650	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102351140	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36425000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35989000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	32000	usd
CY2023Q1	jspr	Issuanceofcommonstockthroughunderwrittenofferingnetofdiscountsandcommissionsandissuancecosts Issuanceofcommonstockthroughunderwrittenofferingnetofdiscountsandcommissionsandissuancecosts	6600	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	96930000	usd
CY2023Q1	jspr	Issuance Of Common Stock Through Atm Offering Net Of Commissions And Offering Cost IssuanceOfCommonStockThroughATMOfferingNetOfCommissionsAndOfferingCost	100	usd
CY2023Q1	jspr	Issuance Of Common Stock Through Atm Offering Net Of Commissions And Offering Costs Of01 M IssuanceOfCommonStockThroughATMOfferingNetOfCommissionsAndOfferingCostsOf01M	4509000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	725000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	6000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1267000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-14260000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	125198000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	320000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	36000	usd
CY2023Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-661000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1391000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-16080000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	110205000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	40000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1395000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-17544000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101242000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	94133000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	69518000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	3000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	778000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2207000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	68105000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1065000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10404000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	58781000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	644000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11863000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	47565000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47884000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24474000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	825000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	702000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-307000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-241000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4053000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2487000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	575000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7050000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-10000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	5640000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1467000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1669000	usd
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-663000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-348000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-102000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1488000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-802000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3245000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-132000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-637000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-386000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-48000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	71000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35588000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33212000	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	37000	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	494000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-494000	usd
	jspr	Proceeds From Issuance Of Common Stock Through Atm And Underwriting Offerings Net ProceedsFromIssuanceOfCommonStockThroughATMAndUnderwritingOfferingsNet	101479000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	36000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	661000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	388000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	65617000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-33679000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38667000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85046000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104284000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51367000	usd
	jspr	Reclassification Of Common Stock Warrant Liability To Equity ReclassificationOfCommonStockWarrantLiabilityToEquity	725000	usd
	jspr	Vesting Of Founders Restricted Stock VestingOfFoundersRestrictedStock	8000	usd
	jspr	Vesting Of Founders Restricted Stock VestingOfFoundersRestrictedStock	7000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1074000	usd
	jspr	Noncash Leasehold Improvements NoncashLeaseholdImprovements	281000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Description of Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Jasper Therapeutics, Inc. and its consolidated subsidiary (collectively, “Jasper” or the “Company”), is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, as well as diseases where targeting hematopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome, and novel stem cell transplant conditioning regimens. The Company is headquartered in Redwood City, California.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 24, 2021 (the “Closing Date”), the Company consummated the previously announced business combination (the “Business Combination” or “Reverse Recapitalization” for accounting purposes) pursuant to the terms of the Business Combination Agreement, dated as of May 5, 2021 (the “BCA”), by and among Amplitude Healthcare Acquisition Corporation (“AMHC”), Ample Merger Sub, Inc., a then-wholly-owned subsidiary of AMHC (“Merger Sub”), and the pre-Business Combination Jasper Therapeutics, Inc. (now named Jasper Tx Corp.) (“Old Jasper”). Pursuant to the terms of the BCA, on the Closing Date, (i) Merger Sub merged with and into Old Jasper, with Old Jasper as the surviving company in the Business Combination, and, after giving effect to such Business Combination, Old Jasper became a wholly owned subsidiary of AMHC and changed its name to “Jasper Tx Corp.”, and (ii) AMHC changed its name to “Jasper Therapeutics, Inc.”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liquidity and Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has incurred significant losses and negative cash flows from operations since its inception. During the three and nine months ended September 30, 2023, the Company incurred net losses of $17.5 million and $47.9 million, respectively. During the three and nine months ended September 30, 2022, the Company incurred net losses of $11.9 million and $24.5 million, respectively. During the nine months ended September 30, 2023 and 2022, the Company had negative operating cash flows of $35.6 million and $33.2 million, respectively. As of September 30, 2023 and December 31, 2022, the Company had an accumulated deficit of $153.0 million and $105.1 million, respectively. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support the Company’s cost structure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of September 30, 2023, the Company had cash and cash equivalents of $103.9 million. The Company’s management expects that the existing cash and cash equivalents will be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. The Company will need to raise additional financing to continue its products’ development for the foreseeable future, and expects to continue doing so until it becomes profitable. The Company’s management plans to monitor expenses and raise additional capital through a combination of public and private equity, debt financings, strategic alliances, and licensing arrangements. The Company’s ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company’s business opportunities, as desired, which could materially harm the Company’s business, financial condition and results of operations.</p>
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-17500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47900000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24500000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33200000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-153000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105100000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, the determination of the accrued research and development expenses, valuation of earnout liability and the measurement of stock-based compensation expense. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</p>
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103867000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38250000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	417000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	417000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104284000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38667000	usd
CY2023Q3	us-gaap	Other Cash Equivalents At Carrying Value OtherCashEquivalentsAtCarryingValue	1000000	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3400000	usd
CY2023Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	102867000	usd
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	102867000	usd
CY2023Q3	us-gaap	Other Liabilities OtherLiabilities	28000	usd
CY2023Q3	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	28000	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	37250000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	37250000	usd
CY2022Q4	jspr	Common Stock Warrant Liability CommonStockWarrantLiability	150000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	18000	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	168000	usd
CY2023Q3	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	28000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	Monte Carlo Simulation
CY2023Q3	us-gaap	Share Price SharePrice	0.7
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y11M23D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.28	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0532	pure
CY2022Q4	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	18000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	Monte Carlo Simulation
CY2022Q4	us-gaap	Share Price SharePrice	0.48
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y8M23D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.05	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.044	pure
CY2023Q3	jspr	Research And Development Prepaid Expenses ResearchAndDevelopmentPrepaidExpenses	481000	usd
CY2022Q4	jspr	Research And Development Prepaid Expenses ResearchAndDevelopmentPrepaidExpenses	842000	usd
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	191000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1362000	usd
CY2023Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	250000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	250000	usd
CY2023Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	18000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	118000	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	411000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	246000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1351000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2818000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2297000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2353000	usd
CY2020Q4	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2300000	usd
CY2023Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2477000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2477000	usd
CY2023Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1743000	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1706000	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	502000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	502000	usd
CY2023Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	145000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	145000	usd
CY2023Q3	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	90000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	90000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4957000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4920000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2177000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1352000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2780000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3568000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	800000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	700000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5883000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2651000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1402000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1587000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	392000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	194000	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7677000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4432000	usd
CY2023Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2264000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2264000	usd
CY2023Q3	jspr	Restricted Stock Liabilities RestrictedStockLiabilities	1000	usd
CY2022Q4	jspr	Restricted Stock Liabilities RestrictedStockLiabilities	9000	usd
CY2023Q3	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	32000	usd
CY2022Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	80000	usd
	jspr	Percentage Of Licensing Fees PercentageOfLicensingFees	0.001	pure
	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.60	pure
CY2023Q3	us-gaap	Investment Interest Rate InvestmentInterestRate	0.25	pure
	jspr	Received Aggregate From Cirm ReceivedAggregateFromCIRM	2300000	usd
CY2023Q3	us-gaap	Cash Cash	700000	usd
CY2023Q3	jspr	Other Receivables Milestone OtherReceivablesMilestone	50000	usd
	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	9000000	usd
	jspr	License Maintenance Fee LicenseMaintenanceFee	25000	usd
	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2026-09-24
CY2023Q3	jspr	Shares Of Nonvoting Common Stock SharesOfNonvotingCommonStock	911022	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4999863	shares
	us-gaap	Equity Fair Value Adjustment EquityFairValueAdjustment	700000	usd
CY2023Q3	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	0	usd
	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	600000	usd
CY2022Q3	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	200000	usd
	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	7100000	usd
CY2022Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	200000	usd
CY2023Q3	jspr	Estimated Fair Value Of Earnout Liability EstimatedFairValueOfEarnoutLiability	100000	usd
CY2022Q4	jspr	Estimated Fair Value Of Earnout Liability EstimatedFairValueOfEarnoutLiability	100000	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	300000	usd
	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	100000	usd
CY2020Q3	jspr	Rentable Square Feet With Lease Commencement RentableSquareFeetWithLeaseCommencement	7781	sqft
CY2022Q1	jspr	Rentable Square Feet With Lease Commencement RentableSquareFeetWithLeaseCommencement	5611	sqft
CY2022Q1	jspr	Agreement For Square Feet Of Temporary Office Space AgreementForSquareFeetOfTemporaryOfficeSpace	5144	sqft
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	26000	usd
CY2022Q3	jspr	Lessor Amount LessorAmount	400000	usd
CY2023Q3	us-gaap	Tenant Improvements TenantImprovements	1500000	usd
CY2023Q3	jspr	Additional Allowance AdditionalAllowance	400000	usd
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	1900000	usd
CY2022	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	1900000	usd
	jspr	Net Construction Costs Percentage NetConstructionCostsPercentage	0.05	pure
	us-gaap	Operating Lease Cost OperatingLeaseCost	504000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	454000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	129000	usd
	us-gaap	Lease Cost LeaseCost	506000	usd
	us-gaap	Lease Cost LeaseCost	583000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	150000000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	834000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	594000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	285000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1153000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1187000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	740000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3365000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	351000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3014000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	945000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2069000	usd
	jspr	Pay Stanford Net PayStanfordNet	900000	usd
	jspr	Pay Stanford Net Term PayStanfordNetTerm	P3Y
	jspr	First Milestone Agremment FirstMilestoneAgremment	300000	usd
	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	300000	usd
	jspr	Third Mile Stone Amount ThirdMileStoneAmount	300000	usd
CY2022Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	25000	usd
CY2023Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	25000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110850413	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110850413	shares
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	19817048	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17334938	shares
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	250000000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9000000	shares
CY2023Q1	jspr	Option To Purchase Of Shares OptionToPurchaseOfShares	9000000	shares
CY2022Q4	jspr	Aggregate Offering Price AggregateOfferingPrice	15500000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	4500000	usd
CY2023Q2	jspr	Aggregate Offering Price AggregateOfferingPrice	75000000	usd
	jspr	Available Offering Amount AvailableOfferingAmount	175000000	usd
CY2023Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	75000000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	The number of shares available for issuance under the 2021 Plan will increase annually in an amount equal to the least of (i) 2,750,000 shares, (ii) a number of shares equal to 4% of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares determined by the Company’s Board of Directors (“Board”) no later than the last day of the immediately preceding fiscal year. The number of shares of common stock available for issuance under the ESPP will increase annually in an amount equal to the least of (i) 550,000 shares of common stock, (ii) a number of shares of common stock equal to 1% of the total number of shares of all classes of common stock of the Company on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Board. As of September 30, 2023, 6,403,566 shares were reserved for issuance under the 2021 Plan, of which 1,086,589 shares were available for future grant and 5,316,977 shares were subject to outstanding options and restricted stock units (“RSUs”), including performance-based awards. As of September 30, 2023, 124,435 shares have been issued under the ESPP and 1,184,572 shares were reserved and available for future issuance.
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1196841	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4303159	shares
	jspr	Fair Market Value Of Common Stock Percentage FairMarketValueOfCommonStockPercentage	0.85	pure
CY2023Q3	us-gaap	Reporting Unit Percentage Of Fair Value In Excess Of Carrying Amount ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount	1	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.10	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	400000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2700000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1000000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.35
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.88
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	10500000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11M15D
CY2023Q4	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	1076814	shares
CY2023Q4	us-gaap	Common Unit Issued CommonUnitIssued	724848	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	65001	shares
CY2023Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	100000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	100000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	100000	usd
	jspr	Proceeds From Issuance Of Common Stock Through Atm And Underwriting Offerings Net ProceedsFromIssuanceOfCommonStockThroughATMAndUnderwritingOfferingsNet		usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1395000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	644000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4053000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2487000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	100000	usd
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	100000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-17544000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11863000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47884000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24474000	usd
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	110813456	shares
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	37983458	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	103495180	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	37913135	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	42715	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	367808	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	94040	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	438135	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109720741	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36565650	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102351140	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36425000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16372578	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11612359	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16372578	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11612359	shares
CY2023Q3	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	100000	usd
CY2022Q3	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	100000	usd
	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	200000	usd
	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	400000	usd
CY2023Q3	us-gaap	Other Receivables OtherReceivables		usd
CY2023Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2023Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2022Q1	jspr	Issuance Of Common Stock Upon Exercise Of Common Stock Warrants IssuanceOfCommonStockUponExerciseOfCommonStockWarrants		usd
CY2022Q2	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2022Q3	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets		usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans		usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
	jspr	Reclassification Of Common Stock Warrant Liability To Equity ReclassificationOfCommonStockWarrantLiabilityToEquity		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	jspr	Noncash Leasehold Improvements NoncashLeaseholdImprovements		usd
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod		shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102351140	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109720741	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36425000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36565650	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001788028

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
jspr-20230930_def.xml	Edgar Link	unprocessable
0001213900-23-084970-index-headers.html	Edgar Link	pending
0001213900-23-084970-index.html	Edgar Link	pending
0001213900-23-084970.txt	Edgar Link	pending
0001213900-23-084970-xbrl.zip	Edgar Link	pending
f10q0923ex31-1_jasperthera.htm	Edgar Link	pending
f10q0923ex31-2_jasperthera.htm	Edgar Link	pending
f10q0923ex32-1_jasperthera.htm	Edgar Link	pending
f10q0923_jasperthera.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
jspr-20230930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
jspr-20230930_cal.xml	Edgar Link	unprocessable
jspr-20230930_lab.xml	Edgar Link	unprocessable
jspr-20230930_pre.xml	Edgar Link	unprocessable
f10q0923_jasperthera_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JSPR
Jasper Therapeutics, Inc. Stock $jspr

2023 Q4 Form 10-Q Financial Statement

#000121390023084970 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JSPR Jasper Therapeutics, Inc. Stock $jspr

2023 Q4 Form 10-Q Financial Statement

#000121390023084970 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JSPR
Jasper Therapeutics, Inc. Stock $jspr